Biofil Chem & Pharma Ltd
₹34.40
-6.50%
Delayed · cached 15 min
Fair value analysis
BIOFILCHEM
Biofil Chem & Pharma Ltd
₹36.79
Close used for this calculation
₹34.46Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
44/100
Quality radar
Consensus fair value
₹34.46
Near FV▼ -6.3% against the close used
Model range ₹9.85 – ₹77.01
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹9.85Fair value₹34.46Bull₹77.01
FairClose
52-week traded range
52W low ₹25.7952W high ₹46.34
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading close to the consensus fair value
Biofil Chem & Pharma Ltd closed at ₹36.79, 6.8% above the consensus fair value of ₹34.46 drawn from 7 valuation models.
Financial DNA score 44/100 — Average. P/E of 117.0x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹13.04
-64.6%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Formula
₹77.01
+109.3%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=20%, FD=7%
P/E Fair Value
₹61.05
+65.9%
EPS × 35.7x (sector P/E)
EPS=1.71, Sector P/E=35.7x
Peter Lynch (PEG)
₹42.75
+16.2%
EPS × Growth% (PEG = 1 is fair)
EPS=1.71, g=25%
EV/EBITDA
₹9.85
-73.2%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=10M
Reverse DCF
₹36.79
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 8.1% | Historical: 25%
Margin of Safety
₹37.78
+2.7%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=50.37, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.